Technical Analysis for ASND - Ascendis Pharma A/S
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 94.95 | 0.94% | 0.88 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Flat | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bullish Engulfing | Bullish | 0.00% | |
Crossed Above 50 DMA | Bullish | 0.00% | |
Hammer Candlestick | Bullish | 0.00% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
50 DMA Resistance | Bearish | 0.94% | |
MACD Bearish Centerline Cross | Bearish | 0.94% | |
Fell Below 50 DMA | Bearish | 0.79% | |
Inside Day | Range Contraction | 0.79% | |
50 DMA Support | Bullish | -0.58% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
50 DMA Support | about 9 hours ago |
Rose Above 50 DMA | about 9 hours ago |
Lower Bollinger Band Support | about 11 hours ago |
60 Minute Opening Range Breakdown | about 12 hours ago |
Fell Below Lower Bollinger Band | about 12 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 10/31/2023
Ascendis Pharma A/S Description
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection. It has strategic collaborations with Sanofi, Genentech, and United Therapeutics Corporation. The company was founded in 2006 and is headquartered in Hellerup, Denmark.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Disease Diabetes Hypertension Insulin Hormones Pulmonary Arterial Hypertension Breakthrough Therapy Peptide Hormones Drug Therapies Growth Hormone Treatment Of Diabetes Growth Hormone Deficiency Recombinant Proteins Growth Hormone Therapy Prodrug Treprostinil
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 134.48 |
52 Week Low | 64.33 |
Average Volume | 283,175 |
200-Day Moving Average | 99.81 |
50-Day Moving Average | 94.91 |
20-Day Moving Average | 98.73 |
10-Day Moving Average | 96.76 |
Average True Range | 3.63 |
RSI (14) | 45.65 |
ADX | 18.85 |
+DI | 14.99 |
-DI | 27.12 |
Chandelier Exit (Long, 3 ATRs) | 95.57 |
Chandelier Exit (Short, 3 ATRs) | 102.47 |
Upper Bollinger Bands | 105.33 |
Lower Bollinger Band | 92.13 |
Percent B (%b) | 0.21 |
BandWidth | 13.37 |
MACD Line | -0.25 |
MACD Signal Line | 0.73 |
MACD Histogram | -0.9858 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 100.13 | ||||
Resistance 3 (R3) | 99.59 | 97.31 | 99.27 | ||
Resistance 2 (R2) | 97.31 | 95.99 | 97.59 | 98.98 | |
Resistance 1 (R1) | 96.13 | 95.18 | 96.72 | 96.68 | 98.69 |
Pivot Point | 93.86 | 93.86 | 94.15 | 94.13 | 93.86 |
Support 1 (S1) | 92.68 | 92.54 | 93.27 | 93.22 | 91.21 |
Support 2 (S2) | 90.40 | 91.72 | 90.68 | 90.92 | |
Support 3 (S3) | 89.22 | 90.40 | 90.63 | ||
Support 4 (S4) | 89.77 |